178 related articles for article (PubMed ID: 21642867)
1. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; Anraku M; de Perrot M
J Thorac Oncol; 2011 Sep; 6(9):1578-86. PubMed ID: 21642867
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
4. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
5. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma.
Wu L; Yun Z; Tagawa T; De la Maza L; Wu MO; Yu J; Zhao Y; de Perrot M
Cancer Immunol Immunother; 2014 Dec; 63(12):1285-96. PubMed ID: 25183171
[TBL] [Abstract][Full Text] [Related]
6. Expression of tumor necrosis factor-α induced protein 8 like-2 contributes to the immunosuppressive property of CD4(+)CD25(+) regulatory T cells in mice.
Luan YY; Yao YM; Zhang L; Dong N; Zhang QH; Yu Y; Sheng ZY
Mol Immunol; 2011 Oct; 49(1-2):219-26. PubMed ID: 21963221
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
8. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
10. Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice.
Couper KN; Blount DG; de Souza JB; Suffia I; Belkaid Y; Riley EM
J Immunol; 2007 Apr; 178(7):4136-46. PubMed ID: 17371969
[TBL] [Abstract][Full Text] [Related]
11. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy.
Needham DJ; Lee JX; Beilharz MW
Biochem Biophys Res Commun; 2006 May; 343(3):684-91. PubMed ID: 16563349
[TBL] [Abstract][Full Text] [Related]
12. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
Chen YQ; Shi HZ; Qin XJ; Mo WN; Liang XD; Huang ZX; Yang HB; Wu C
Am J Respir Crit Care Med; 2005 Dec; 172(11):1434-9. PubMed ID: 16151041
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
15. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
17. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
Setiady YY; Coccia JA; Park PU
Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells restrain CD4+ T cells from causing unregulated immune activation and hypersensitivity to lipopolysaccharide challenge.
Okeke EB; Okwor I; Uzonna JE
J Immunol; 2014 Jul; 193(2):655-62. PubMed ID: 24943218
[TBL] [Abstract][Full Text] [Related]
19. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.
Hong SH; Yoon IH; Kim YH; Yang SH; Park MJ; Nam HY; Kim B; Kim Y; Park CS; Park CG
Immunobiology; 2010 Mar; 215(3):182-93. PubMed ID: 19464751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
